9,457 Shares in Pacira BioSciences, Inc. $PCRX Acquired by FORA Capital LLC

Key Points

• FORA Capital LLC has acquired 9,457 shares of Pacira BioSciences, Inc. valued at approximately $235,000, marking its entry into a significant position in the company.
• Wall Street analysts have recently upgraded Pacira BioSciences' stock rating, with five analysts now recommending a buy rating and a consensus price target of $30.83.
• Pacira BioSciences reported earnings of $0.74 per share for the last quarter, slightly exceeding analysts' expectations, with a revenue increase of 1.7% year-over-year.

FORA Capital LLC acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,457 shares of the company's stock, valued at approximately $235,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. State of Wyoming lifted its holdings in Pacira BioSciences by 8.0% in the 4th quarter. State of Wyoming now owns 6,566 shares of the company's stock valued at $124,000 after acquiring an additional 487 shares during the last quarter. US Bancorp DE lifted its holdings in Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after acquiring an additional 537 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Pacira BioSciences by 3.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock valued at $491,000 after acquiring an additional 794 shares during the last quarter. Corton Capital Inc. lifted its holdings in Pacira BioSciences by 6.0% in the 4th quarter. Corton Capital Inc. now owns 21,575 shares of the company's stock valued at $406,000 after acquiring an additional 1,214 shares during the last quarter. Finally, Ancora Advisors LLC acquired a new stake in Pacira BioSciences in the 4th quarter valued at about $26,000. 99.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PCRX shares. Needham & Company LLC cut their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. Zacks Research raised shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. Truist Financial raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price target for the company in a report on Friday, July 25th. Finally, Wall Street Zen upgraded Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Pacira BioSciences currently has an average rating of "Moderate Buy" and an average target price of $30.83.

Insider Buying and Selling at Pacira BioSciences

In other news, Director Marcelo Bigal sold 4,912 shares of the company's stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the transaction, the director owned 11,393 shares in the company, valued at $269,672.31. This represents a 30.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.40% of the stock is owned by corporate insiders.

Pacira BioSciences Stock Down 1.7%

Shares of PCRX traded down $0.45 during trading hours on Thursday, reaching $26.73. The company's stock had a trading volume of 773,687 shares, compared to its average volume of 680,071. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -9.62 and a beta of 0.42. Pacira BioSciences, Inc. has a 1-year low of $12.61 and a 1-year high of $27.64. The company has a quick ratio of 1.91, a current ratio of 2.38 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average of $23.91 and a two-hundred day moving average of $24.59.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.73 by $0.01. The company had revenue of $181.10 million for the quarter, compared to the consensus estimate of $183.11 million. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The firm's quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.96 EPS. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, research analysts predict that Pacira BioSciences, Inc. will post 2.41 EPS for the current fiscal year.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.